Cybin (R7E) Stock Overview
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
R7E Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cybin Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.15 |
| 52 Week High | US$8.85 |
| 52 Week Low | US$4.22 |
| Beta | 0.85 |
| 1 Month Change | -26.95% |
| 3 Month Change | 3.83% |
| 1 Year Change | -41.48% |
| 3 Year Change | -64.67% |
| 5 Year Change | -88.89% |
| Change since IPO | -92.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| R7E | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 9.1% | -1.7% | 0.1% |
| 1Y | -41.5% | 26.1% | 5.3% |
Return vs Industry: R7E underperformed the German Pharmaceuticals industry which returned 26.1% over the past year.
Return vs Market: R7E underperformed the German Market which returned 5.3% over the past year.
Price Volatility
| R7E volatility | |
|---|---|
| R7E Average Weekly Movement | 17.3% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: R7E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R7E's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Mike Cola | cybin.com |
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.
Cybin Inc. Fundamentals Summary
| R7E fundamental statistics | |
|---|---|
| Market cap | €256.02m |
| Earnings (TTM) | -€103.80m |
| Revenue (TTM) | n/a |
Is R7E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R7E income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$123.22m |
| Earnings | -US$123.22m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did R7E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/16 10:13 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cybin Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |